Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma

P. C. Huijgens; A. R. Jonkhoff; O. S. Hoekstra; G. J. Ossenkoppele; G. J.J. Teule

doi:https://doi.org/10.1111/j.1600-0609.1993.tb00631.x

Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma

P. C. Huijgens, A. R. Jonkhoff, O. S. Hoekstra, G. J. Ossenkoppele, G. J.J. Teule

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

Abstract: 67‐gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human‐derived cell‐lines. 67‐gallium was given intravenously to 3 patients with end‐stage, resistant large‐cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT‐scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Panycytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67‐gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.

Original language	English
Pages (from-to)	206-208
Number of pages	3
Journal	European journal of haematology
Volume	51
Issue number	4
DOIs	https://doi.org/10.1111/j.1600-0609.1993.tb00631.x
Publication status	Published - Oct 1993

Keywords

67‐gallium
non‐Hodgkin's lymphoma

Access to Document

https://doi.org/10.1111/j.1600-0609.1993.tb00631.x

Cite this

@article{4695737976a24498b482ed55f87804e2,

title = "Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma",

abstract = "Abstract: 67‐gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human‐derived cell‐lines. 67‐gallium was given intravenously to 3 patients with end‐stage, resistant large‐cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT‐scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Panycytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67‐gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.",

keywords = "67‐gallium, non‐Hodgkin's lymphoma",

author = "Huijgens, {P. C.} and Jonkhoff, {A. R.} and Hoekstra, {O. S.} and Ossenkoppele, {G. J.} and Teule, {G. J.J.}",

year = "1993",

month = oct,

doi = "https://doi.org/10.1111/j.1600-0609.1993.tb00631.x",

language = "English",

volume = "51",

pages = "206--208",

journal = "European journal of haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma

AU - Huijgens, P. C.

AU - Jonkhoff, A. R.

AU - Hoekstra, O. S.

AU - Ossenkoppele, G. J.

AU - Teule, G. J.J.

PY - 1993/10

Y1 - 1993/10

N2 - Abstract: 67‐gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human‐derived cell‐lines. 67‐gallium was given intravenously to 3 patients with end‐stage, resistant large‐cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT‐scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Panycytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67‐gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.

AB - Abstract: 67‐gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human‐derived cell‐lines. 67‐gallium was given intravenously to 3 patients with end‐stage, resistant large‐cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT‐scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Panycytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67‐gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.

KW - 67‐gallium

KW - non‐Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0027134870&partnerID=8YFLogxK

U2 - https://doi.org/10.1111/j.1600-0609.1993.tb00631.x

DO - https://doi.org/10.1111/j.1600-0609.1993.tb00631.x

M3 - Article

C2 - 8243608

SN - 0902-4441

VL - 51

SP - 206

EP - 208

JO - European journal of haematology

JF - European journal of haematology

IS - 4

ER -

Therapeutic potential of intravenous 67‐gallium in non‐Hodgkin's lymphoma

Abstract

Keywords

Access to Document

Other files and links

Cite this